Since December 2019, the novel coronavirus epidemic has spread worldwide. The WHO (WHO) has classified the new coronavirus epidemic as a public health emergencies of international concern (PHEIC). In the face of unexpected problems, we have found a common ingredient in many therapeutic drugs, kaempferol, which has played an important role in anti-virus and anti-inflammatory during the epidemic.
Kaempferol is insoluble in water, which limits its application in anti-virus and anti-inflammation, while glycosylation can enhance the water solubility of phenols, which is beneficial to the absorption of drugs, and may even enhance the properties of some aspects. we want to verify whether the water solubility of kaempferol will be enhanced by adding 1 or 2 glycosyl groups, and whether its anti-inflammation still exists, or even stronger.
The plasmid of glycosylated kaempferol
Two plasmids carrying two UDP glycosyltransferases were designed. Kaempferol was added 1 or 2 glycosyl groups by transforming E. coli DE3, to obtain Astragalin and Kaempferol 3-O-glucoside-7-O-rhamnoside. The recombinant E. coli was cultured overnight, IPTG was added to induce the expression of the recombinant protein, and then the protein was purified to construct an in vitro enzymatic reaction system to produce the product under suitable conditions.
Finally, the glycosylation products of kaempferol were detected and purified by HPLC combined with mass spectrometry.
After obtaining the product, we test its water solubility and anti-inflammation, and compare it with the kaempferol control group to verify whether glycosylation can improve the water solubility of kaempferol and whether it can maintain or even enhance its anti-inflammation.
On the one hand, we will work with the NWU-CHINA-A team to put the product on the band-aid. Our glycosylated kaempferol combines with their antimicrobial peptides to produce antibacterial and anti-inflammatory band-aids that can effectively prevent wound infection.
On the other hand, in the future, we also hope to work with pharmaceutical companies to add glycosylated kaempferol to drugs to treat inflammation caused by viruses and bacteria.
